Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1951 1
1956 1
1964 1
1965 1
1966 3
1967 2
1968 1
1969 1
1970 1
1971 4
1972 2
1973 2
1976 3
1977 2
1978 4
1979 7
1980 2
1981 3
1982 4
1983 1
1984 8
1985 8
1986 4
1987 12
1988 31
1989 36
1990 39
1991 44
1992 32
1993 30
1994 39
1995 55
1996 39
1997 47
1998 63
1999 74
2000 107
2001 135
2002 136
2003 130
2004 161
2005 161
2006 191
2007 188
2008 214
2009 230
2010 244
2011 227
2012 230
2013 300
2014 490
2015 560
2016 612
2017 617
2018 607
2019 655
2020 709
2021 803
2022 791
2023 792
2024 295

Text availability

Article attribute

Article type

Publication date

Search Results

8,907 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20Axel, 20Louembe
Page 1
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Dasari A, et al. Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15. Lancet. 2023. PMID: 37331369 Clinical Trial.
METHODS: We conducted an international, randomised, double-blind, placebo-controlled, phase 3 study (FRESCO-2) at 124 hospitals and cancer centres across 14 countries. We included patients aged 18 years or older (20 years in Japan) with histologically or cytologically docu …
METHODS: We conducted an international, randomised, double-blind, placebo-controlled, phase 3 study (FRESCO-2) at 124 hospitals and cancer c …
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators. Luke JJ, et al. Lancet. 2022 Apr 30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1. Lancet. 2022. PMID: 35367007 Clinical Trial.
At the second interim analysis (data cutoff on June 21, 2021; median follow-up of 20.9 months [16.7-25.3] in the pembrolizumab group and 20.9 months [16.6-25.3] in the placebo group), 72 (15%) patients in the pembrolizumab group and 115 (24%) in the placebo group ha …
At the second interim analysis (data cutoff on June 21, 2021; median follow-up of 20.9 months [16.7-25.3] in the pembrolizumab group …
Editorial.
Sabatier JM. Sabatier JM. Infect Disord Drug Targets. 2016;16(2):78. doi: 10.2174/187152651602160610180248. Infect Disord Drug Targets. 2016. PMID: 27345968 No abstract available.
Reply.
Kirchgesner J, Beaugerie L. Kirchgesner J, et al. Clin Gastroenterol Hepatol. 2022 Feb;20(2):e345. doi: 10.1016/j.cgh.2021.05.047. Epub 2021 May 28. Clin Gastroenterol Hepatol. 2022. PMID: 34058409 No abstract available.
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.
Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, van Akkooi A, Bataille V, Bastholt L, Dreno B, Dummer R, Fargnoli MC, Forsea AM, Harwood CA, Hauschild A, Hoeller C, Kandolf-Sekulovic L, Kaufmann R, Kelleners-Smeets NW, Lallas A, Leiter U, Malvehy J, Del Marmol V, Moreno-Ramirez D, Pellacani G, Peris K, Saiag P, Tagliaferri L, Trakatelli M, Ioannides D, Vieira R, Zalaudek I, Arenberger P, Eggermont AMM, Röcken M, Grob JJ, Lorigan P; EADO, EDF, ESTRO, UEMS, EADV and EORTC. Stratigos AJ, et al. Eur J Cancer. 2023 Nov;193:113251. doi: 10.1016/j.ejca.2023.113251. Epub 2023 Jul 28. Eur J Cancer. 2023. PMID: 37717283 Free article.
Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in white populations, accounting for 20% of all cutaneous malignancies. Overall, cSCC mostly has very good prognosis after treatment, with 5-year cure rates greater than 90%. ...
Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in white populations, accounting for 20% of all c …
[Retronychia].
Richert B, Caucanas M, André J. Richert B, et al. Ann Dermatol Venereol. 2014 Dec;141(12):799-804. doi: 10.1016/j.annder.2014.09.027. Epub 2014 Oct 22. Ann Dermatol Venereol. 2014. PMID: 25433936 Review. French. No abstract available.
Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC. Menzer C, et al. J Clin Oncol. 2019 Nov 20;37(33):3142-3151. doi: 10.1200/JCO.19.00489. Epub 2019 Oct 3. J Clin Oncol. 2019. PMID: 31580757 Free PMC article.
Of the 58 patients with V600 mutations, overall response rate to BRAFi monotherapy and combination BRAFi/MEKi was 27% (six of 22) and 56% (20 of 36), respectively, whereas median progression-free survival (PFS) was 3.7 months and 8.0 months, respectively (P = .002). ...
Of the 58 patients with V600 mutations, overall response rate to BRAFi monotherapy and combination BRAFi/MEKi was 27% (six of 22) and 56% ( …
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler TK, Hauschild A, Kiecker F, Hassel JC, Mohr P, Fluck M, Thomas I, Garzarolli M, Grimmelmann I, Drexler K, Spillner AN, Eckhardt S, Schadendorf D; DeCOG. Becker JC, et al. Lancet. 2023 Sep 2;402(10404):798-808. doi: 10.1016/S0140-6736(23)00769-9. Epub 2023 Jul 11. Lancet. 2023. PMID: 37451295 Clinical Trial.
METHODS: In this multicentre phase 2 trial, patients (any stage, Eastern Cooperative Oncology Group performance status 0-1) at 20 academic medical centres in Germany and the Netherlands with completely resected MCC lesions were randomly assigned 2:1 to receive nivolumab 48 …
METHODS: In this multicentre phase 2 trial, patients (any stage, Eastern Cooperative Oncology Group performance status 0-1) at 20 aca …
PCSK9 and the nervous system: a no-brainer?
Jaafar AK, Techer R, Chemello K, Lambert G, Bourane S. Jaafar AK, et al. J Lipid Res. 2023 Sep;64(9):100426. doi: 10.1016/j.jlr.2023.100426. Epub 2023 Aug 14. J Lipid Res. 2023. PMID: 37586604 Free PMC article. Review.
In the past 20 years, PCSK9 has been shown to play a pivotal role in LDL cholesterol metabolism and cardiovascular health by inducing the lysosomal degradation of the LDL receptor. ...
In the past 20 years, PCSK9 has been shown to play a pivotal role in LDL cholesterol metabolism and cardiovascular health by inducing …
8,907 results